ARM Rallies 15% to $256.59 on Vera Royalties Worth at Most $150M Annually
Nvidia's Vera CPU carries a roughly $20B standalone revenue run rate, but ARM's realistic royalty take is $50-150M per year, far below the $400M-$1B consensus baking into a 100x forward P/E. At four times NVDA's multiple on a fraction of its growth, ARM's valuation gap is the clearest repricing risk in the ^IXIC semico
RKey facts
What's happening
ARM Holdings surged 15% on May 22 in response to Nvidia's Q1 earnings disclosure that the Vera CPU will generate approximately $20B in standalone revenue in its first full year of deployment. The math is straightforward: if ARM captures 2-5% of that revenue in royalties or licensing fees, the company could see $400M to $1B in incremental annual revenue flowing through to its bottom line.
Yet the market's pricing of ARM relative to Nvidia reveals a troubling gap in valuation discipline. ARM is trading at a forward P/E of roughly 100x, while Nvidia trades at 25x despite 262% growth and $81.6B in quarterly revenue. This disparity suggests that investors are pricing ARM not on its intrinsic Vera royalty contribution, but on narrative euphoria around AI semiconductor licensing as a category.
Nvidia's disclosure of Vera's revenue run rate was itself a mixed signal. The company telegraphed that standalone Vera will hit $20B in annualized revenue, but this is spread across multiple design-ins and customer partnerships. ARM's licensing take is not a 2-5% of gross revenue share; it is closer to a 2-5% of ARM's installed base of customers who will adopt Vera. Given that Nvidia's own margin on Vera is likely 60-70%, ARM's royalty contribution to net income is likely closer to $50-150M annually, not $400M-$1B.
The bull case for ARM rests on the assumption that Vera is just the first of multiple Nvidia-branded CPUs and that ARM's IP will power a growing slice of hyperscaler infrastructure. But until ARM's management provides more granular guidanceCompany-issued forecasts of future financial performance. on Vera's true contribution and the breadth of follow-on products, the 100x multiple remains hard to justify. The 15% pop looks more like a brief momentumThe empirical fact that winners keep winning over the medium term. trade than a fundamental rerating.
What to watch next
- 01ARM Q2 earnings: watch for Vera royalty guidanceCompany-issued forecasts of future financial performance. and customer design-in pipeline
- 02Nvidia Vera customer wins: tracking major hyperscaler adoption timelines
- 03Valuation reset risk: if ARM guidanceCompany-issued forecasts of future financial performance. disappoints, multiple compression likely
- Yahoo FinanceBlackBerry Soars 18%, Mobileye Climbs 4%, Aurora Innovation Rises 2% While NVIDIA Drifts: Automotive AI Trade Picks a New Leader21m ago
- PR Newswire FinancialEightco Holdings (NASDAQ: ORBS) meldet Gesamtbestände von etwa 337 Mio. USD, darunter OpenAI, Beast Industries, mehr als 11.000 ETH und über 283 Millionen WLD-Token
Zusammensetzung der Treasury-Bestände von Eightco zum 20. Mai 2026: 90 Mio. USD OpenAI-Aktien (indirekt), 18 Mio. USD Beast Industries-Aktien, 11.068 ETH, 283 Mio. WLD-Bestände und 133 Mio. USD Zahlungsmittel und Zahlungsmitteläquivalente, insgesamt etwa 337 Mio. USD World bietet eine...
32m ago - CointelegraphCrypto Biz: Institutions tighten their grip on Bitcoin, AI and prediction markets
Institutional crypto adoption accelerates as Tether expands Bitcoin holdings, miners pivot to AI and Polymarket joins Nasdaq amid $1 billion fund outflows.
54m ago - PR Newswire FinancialAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, May 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). IF YOU SUFFERED A LOSS ON YOUR...
57m ago - PR Newswire FinancialMedpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, May 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). IF YOU SUFFERED A LOSS ON YOUR...
57m ago - Nikkei AsiaKOSPI jumps 8.4% on Samsung strike suspension, Nvidia results1h ago
- Nikkei AsiaKawasaki Heavy to partner with Nvidia on physical AI, open US robot center1h ago
- Nikkei AsiaEditor's Choice: Nvidia and Asia's three chip giants cash in on AI gold rush1h ago
Related coverage
- ARM Reprices to 100x Forward P/E on Vera Royalties Analysts Cap at $400M-$1BTech & AI··0 mentions
- NVDA $91B Q2 Guidance Holds Firm Despite 33x Forward P/E and China ExclusionTech & AI··0 mentions
- NVDA Q1 Revenue $81.6B and $91B Q2 Guide Put 33x Forward P/E in FocusTech & AI··0 mentions
- NVDA $91B Guidance Confirms AI Capex Cycle, ARM Gains 15% on RepricingTech & AI··0 mentions
More about $ARM
- ARM Rallies 15% to $256.59 But Vera Royalties Capped at $400M vs. 100x Forward P/E·Tech & AI
- ARM Reprices to 100x Forward P/E on Vera Royalties Analysts Cap at $400M-$1B·Tech & AI
- NVDA $91B Q2 Guidance Holds Firm Despite 33x Forward P/E and China Exclusion·Tech & AI
- ARM Surges 15% to $256.59 at 100x Forward P/E on NVDA Vera Royalty Expectations·Tech & AI
- NVDA Q1 Revenue $81.6B and $91B Q2 Guide Put 33x Forward P/E in Focus·Tech & AI
Live coverage of the AI semiconductor cycle — NVDA, AVGO, AMD, ASML, memory demand, capex run rates and overbought signals.